Skip to main
RNXT

RenovoRx (RNXT) Stock Forecast & Price Target

RenovoRx (RNXT) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

RenovoRx Inc has demonstrated a notable increase in revenue, reporting $422,000 in Q2, a significant rise from $197,000 in Q1. The company is projected to experience substantial revenue growth, with expectations of reaching $1.3 million in 2025 and $4.5 million in 2026. This anticipated growth reflects the strong market potential of RenovoRx's proprietary Trans-Arterial Micro-Perfusion therapy platform, designed to address high unmet medical needs in cancer treatment.

Bears say

RenovoRx's financial performance reflects ongoing challenges, evidenced by a revenue of only $0.3 to $0.4 million coupled with a net loss of $2.9 million, resulting in an earnings per share (EPS) of $(0.08), which aligns with consensus estimates but underscores a lack of profitability. The company's focus on treating pancreatic cancer, which has a dismal 5-year survival rate of only 12%, raises questions regarding the market viability of its therapeutic approaches amidst significant unmet medical needs. Despite some potential for growth, the overarching risk factors and persistent financial losses contribute to a negative outlook for RenovoRx's stock.

RenovoRx (RNXT) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RenovoRx (RNXT) Forecast

Analysts have given RenovoRx (RNXT) a Strong Buy based on their latest research and market trends.

According to 2 analysts, RenovoRx (RNXT) has a Strong Buy consensus rating as of Jan 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RenovoRx (RNXT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.